Tango Therapeutics (TNGX) EBT Margin (2020 - 2025)

Tango Therapeutics' EBT Margin history runs 6 years deep, the most recent figure standing at 29.5% for Q3 2025.

• On a quarterly basis, EBT Margin rose 28032.0% year-over-year to 29.5% in Q3 2025; TTM through Mar 2026 was 188.2%, a 13397.0% increase from a year earlier, with the FY2025 full-year figure at 162.85%, up 14639.0% from the prior year.
• EBT Margin rose to 29.5% in Q3 2025 per TNGX's latest filing, from 1220.31% in the prior quarter.
• Across five years, EBT Margin topped out at 29.5% in Q3 2025 and bottomed at 1220.31% in Q2 2025.
• The 5-year median for EBT Margin is 419.8% (2022), against an average of 412.22%.
• Across the five-year window, EBT Margin jumped 28926 bps in 2023 and sank 109208 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 382.59% in 2021, then fell by 18 bps to 452.49% in 2022, then declined by 25 bps to 565.57% in 2023, then sank by 62 bps to 913.8% in 2024, then soared by 103 bps to 29.5% in 2025.
• Per Business Quant, the three latest TNGX EBT Margin figures stand at 29.5% (Q3 2025), 1220.31% (Q2 2025), and 738.91% (Q1 2025).